NCT01012362

Study of Pazopanib and Ixabepilone in Patients With Solid Tumors

Phase I Study of Pazopanib and Ixabepilone in Patients With Solid Tumors

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 31 (actual)
• Sponsor: Masonic Cancer Center, University of Minnesota · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase I study; dose escalating the combination of pazopanib when taken daily and ixabepilone when administered on day 1 of a 3 week treatment course.

Detailed description

Treatment with ixabepilone will be given at an assigned dose as a 3 hour intravenous infusion on day 1 of a 21 day cycle. Treatment with pazopanib will be given at an assigned dose by mouth once a day, beginning on day 1 and continuing daily. Disease assessment will be done every 2 cycles (6 weeks) with treatment continuing until disease progression, unacceptable toxicity or patient refusal.

Conditions

• Breast Cancer
• Lung Cancer
• Colon Cancer
• Pancreatic Cancer
• Head and Neck Cancer
• Kidney Cancer
• Sarcoma
• Hepatocellular Cancer

Interventions

Type	Name	Description
DRUG	Pazopanib	Escalating doses 400-800 mg by mouth once daily beginning day 1 and continuing.
DRUG	Ixabepilone	Escalating doses 25-32 mg/m2 by intravenous infusion on day 1 of each 21 day cycle

Timeline

• Start date: 2009-12-01
• Primary completion: 2013-02-01
• Completion: 2013-02-01
• First posted: 2009-11-13
• Last updated: 2017-12-28
• Results posted: 2017-06-26

Locations

1 site across 1 country: United States